Cancer Drug Resistance Linked to Cellular Aging Process Scientists Can Now Target

This groundbreaking research reveals why platinum-based chemotherapy often fails in lung and ovarian cancers and offers a promising solution. These cancers remain among the deadliest, partly because tumors develop resistance to standard platinum drugs like cisplatin.

Researchers studied multiple laboratory models of non-small cell lung cancer and high-grade serous ovarian cancer, using mouse models and patient tissue samples. They discovered that cisplatin doesn't just kill cancer cells—it also triggers cellular senescence, a state where cells stop dividing but remain metabolically active.

The key finding was that these senescent cells release a cocktail of inflammatory proteins called SASP (senescence-associated secretory phenotype), particularly rich in TGFβ. Rather than helping fight cancer, this inflammatory environment actually promotes tumor growth by activating survival pathways in remaining cancer cells through TGFBR1 and AKT/mTOR signaling. The effect was worse in older organisms, suggesting aging compounds the problem.

When researchers combined standard chemotherapy with drugs that either blocked TGFβ signaling (galunisertib) or eliminated senescent cells (senolytics), tumor growth decreased significantly and survival improved. Importantly, they validated these findings in tissue samples from actual cancer patients who had received platinum chemotherapy, showing elevated TGFβ-rich SASP.

This research has profound implications for cancer treatment and healthy aging. It suggests that targeting cellular senescence—a hallmark of aging—could improve cancer outcomes. The identified drug combinations use existing medications, potentially accelerating clinical translation. For longevity-focused individuals, this highlights how aging processes intersect with disease resistance and why maintaining cellular health becomes increasingly important with age.